SERUM MYELOPEROXIDASE, MALONDIALDEHYDE, ALPHA-SYNUCLEIN LEVELS IN PATIENTS WITH EPILEPSY

Background: Processes such as neurodegeneration, hypoxia, blood brain barrier dysfunction and oxidative changes are effective for epileptogenesis.There is no non-invasive biomarker that can be used in the follow-up of patients with epilepsy, which is a neurodegenerative disease. Objective: In ou...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fatma Şimşek, Mustafa Ceylan, Seda Aşkın, Ahmet Kızıltunç
Formato:	article
Lenguaje:	EN ID
Publicado:	University of Brawijaya 2021
Materias:	epilepsy myeloperoxidase malondialdehyde alpha-synuclein Medicine R Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/b7263580af3a421b9d8d6206fc5601e8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b7263580af3a421b9d8d6206fc5601e8
record_format	dspace
spelling	oai:doaj.org-article:b7263580af3a421b9d8d6206fc5601e82021-11-24T05:12:24ZSERUM MYELOPEROXIDASE, MALONDIALDEHYDE, ALPHA-SYNUCLEIN LEVELS IN PATIENTS WITH EPILEPSY10.21776/ub.mnj.2021.007.02.22407-67242442-5001https://doaj.org/article/b7263580af3a421b9d8d6206fc5601e82021-07-01T00:00:00Zhttps://mnj.ub.ac.id/index.php/mnj/article/view/519https://doaj.org/toc/2407-6724https://doaj.org/toc/2442-5001Background: Processes such as neurodegeneration, hypoxia, blood brain barrier dysfunction and oxidative changes are effective for epileptogenesis.There is no non-invasive biomarker that can be used in the follow-up of patients with epilepsy, which is a neurodegenerative disease. Objective: In our study, it was aimed to investigate the relationship between inflammatory, oxidative, neurodegenerative processes, and antiepileptic use in patients with epilepsy. Methods: The groups were formed from the patients who were followed up in the epilepsy outpatient clinic between April 2019-June 2019, and the age-gender-matched control group.The study included 30 patients and 30 healthy volunteers. Venous serum samples were collected from groups to study myeloperoxidase, malondialdehyde and alpha-synuclein. Results: The levels of myeloperoxidase and malondialdehyde were higher in the control group and this difference was statistically significant (p=0.003, p<0.001). The level of α-syn was higher in the epilepsy group and there was no statistically significant difference between the two groups (p=0.52). There was a positive correlation between the α-syn level and disease duration and as the disease duration increased, the level of α-syn increased (r=0.379, p=0.03). Conclusion: Although the α-syn level increases with the duration of the disease in epilepsy patients, it is not a suitable parameter for use as a biomarker in the follow-up.Fatma ŞimşekMustafa CeylanSeda AşkınAhmet KızıltunçUniversity of Brawijayaarticleepilepsymyeloperoxidasemalondialdehydealpha-synucleinMedicineRNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENIDMalang Neurology Journal, Vol 7, Iss 2, Pp 93-97 (2021)
institution	DOAJ
collection	DOAJ
language	EN ID
topic	epilepsy myeloperoxidase malondialdehyde alpha-synuclein Medicine R Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	epilepsy myeloperoxidase malondialdehyde alpha-synuclein Medicine R Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Fatma Şimşek Mustafa Ceylan Seda Aşkın Ahmet Kızıltunç SERUM MYELOPEROXIDASE, MALONDIALDEHYDE, ALPHA-SYNUCLEIN LEVELS IN PATIENTS WITH EPILEPSY
description	Background: Processes such as neurodegeneration, hypoxia, blood brain barrier dysfunction and oxidative changes are effective for epileptogenesis.There is no non-invasive biomarker that can be used in the follow-up of patients with epilepsy, which is a neurodegenerative disease. Objective: In our study, it was aimed to investigate the relationship between inflammatory, oxidative, neurodegenerative processes, and antiepileptic use in patients with epilepsy. Methods: The groups were formed from the patients who were followed up in the epilepsy outpatient clinic between April 2019-June 2019, and the age-gender-matched control group.The study included 30 patients and 30 healthy volunteers. Venous serum samples were collected from groups to study myeloperoxidase, malondialdehyde and alpha-synuclein. Results: The levels of myeloperoxidase and malondialdehyde were higher in the control group and this difference was statistically significant (p=0.003, p<0.001). The level of α-syn was higher in the epilepsy group and there was no statistically significant difference between the two groups (p=0.52). There was a positive correlation between the α-syn level and disease duration and as the disease duration increased, the level of α-syn increased (r=0.379, p=0.03). Conclusion: Although the α-syn level increases with the duration of the disease in epilepsy patients, it is not a suitable parameter for use as a biomarker in the follow-up.
format	article
author	Fatma Şimşek Mustafa Ceylan Seda Aşkın Ahmet Kızıltunç
author_facet	Fatma Şimşek Mustafa Ceylan Seda Aşkın Ahmet Kızıltunç
author_sort	Fatma Şimşek
title	SERUM MYELOPEROXIDASE, MALONDIALDEHYDE, ALPHA-SYNUCLEIN LEVELS IN PATIENTS WITH EPILEPSY
title_short	SERUM MYELOPEROXIDASE, MALONDIALDEHYDE, ALPHA-SYNUCLEIN LEVELS IN PATIENTS WITH EPILEPSY
title_full	SERUM MYELOPEROXIDASE, MALONDIALDEHYDE, ALPHA-SYNUCLEIN LEVELS IN PATIENTS WITH EPILEPSY
title_fullStr	SERUM MYELOPEROXIDASE, MALONDIALDEHYDE, ALPHA-SYNUCLEIN LEVELS IN PATIENTS WITH EPILEPSY
title_full_unstemmed	SERUM MYELOPEROXIDASE, MALONDIALDEHYDE, ALPHA-SYNUCLEIN LEVELS IN PATIENTS WITH EPILEPSY
title_sort	serum myeloperoxidase, malondialdehyde, alpha-synuclein levels in patients with epilepsy
publisher	University of Brawijaya
publishDate	2021
url	https://doaj.org/article/b7263580af3a421b9d8d6206fc5601e8
work_keys_str_mv	AT fatmasimsek serummyeloperoxidasemalondialdehydealphasynucleinlevelsinpatientswithepilepsy AT mustafaceylan serummyeloperoxidasemalondialdehydealphasynucleinlevelsinpatientswithepilepsy AT sedaaskın serummyeloperoxidasemalondialdehydealphasynucleinlevelsinpatientswithepilepsy AT ahmetkızıltunc serummyeloperoxidasemalondialdehydealphasynucleinlevelsinpatientswithepilepsy
_version_	1718415935611600896

SERUM MYELOPEROXIDASE, MALONDIALDEHYDE, ALPHA-SYNUCLEIN LEVELS IN PATIENTS WITH EPILEPSY

Ejemplares similares